Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 7

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 7
---
 of the applicable exchange; |

| • |     | privately negotiated transactions; |

| • |     | settlement of short sales entered into after the date of this prospectus supplement; |

| • |     | broker-dealers may agree with the Selling Stockholder to sell a specified number of such Shares at a stipulated 
 price per Share;                                                                                                |

| • |     | through the writing or settlement of options or other hedging transactions, whether such options are listed on an 
 options exchange or otherwise; or                                                                                 |

| • |     | a combination of any such methods of sale; and any other method permitted pursuant to applicable law. |

The Selling Stockholder also may resell all or a portion of the Shares in open market transactions in reliance upon Rule 144 under the Securities Act as permitted by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus supplement, providedthat they meet the criteria and conform to the requirements of those provisions. Broker-dealers engaged by the Selling Stockholder may arrange for other broker-dealers to participate in sales. If the Selling Stockholder effects such transactions by selling Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholder or commissions from purchasers of the Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2121.01.In connection with sales of the Shares or otherwise, the Selling Stockholder may enter into hedging transactions with broker-dealers or S-8

other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The Selling Stockholder may also sell Shares short and if
such short sale shall take place after the date that this registration statement is declared effective by the SEC, the Selling Stockholder may deliver Shares covered by this prospectus supplement to close out short positions and to return borrowed
shares in connection with such short sales. The Selling Stockholder may also loan or pledge Shares to broker-dealers that in turn may sell such Shares, to